ArticleNature genetics2023
SARS-CoV-2 diagnostic testing rates determine the sensitivity of genomic surveillance programs.
Article in Nature genetics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 33 citations in OpenAlex.
- Smartphone-Based Peptide Nucleic Acid (PNA) Probe-Assisted Potentiometric Biosensor for Point-of-Care Testing of SARS-CoV-2 Nucleic Acid.Analytical chemistry · 2026Article
- Early Detection Intervals for Evaluating Event-Based Surveillance System: Reference Dataset Development Study.JMIR public health and surveillance · 2026Article
- A High-Throughput Platform for Rapid Adaptation of DNA Aptamers to SARS-CoV-2 Evolution.bioRxiv : the preprint server for biology · 2026Article
- Optimizing global genomic surveillance for early detection of emerging SARS-CoV-2 variants.Nature communications · 2026Article
- The Representativeness of Regional Influenza Virus Genomic Surveillance for National Trends in the United States.medRxiv : the preprint server for health sciences · 2026Article
- Global solidarity in genomic surveillance improves early detection of acute respiratory virus threats.Nature communications · 2026Article
- The Crucial Role of Laboratory Medicine in Addressing Future Public Health Infectious Threats: Insights Gained from the COVID-19 Pandemic.Diagnostics (Basel, Switzerland) · 2025Article
- Optimizing resources in genomic surveillance: South Carolina's QC-plus approach.Frontiers in public health · 2025Article
- Toward optimal disease surveillance with graph-based active learning.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Surveillance strategies for the detection of new pathogen variants across epidemiological contexts.PLoS computational biology · 2024Article
- Risk of COVID-19 in Children throughout the Pandemic and the Role of Vaccination: A Narrative Review.Vaccines · 2024Review
- Drivers and impact of the early silent invasion of SARS-CoV-2 Alpha.Nature communications · 2024Article
- Impact and cost-effectiveness of SARS-CoV-2 self-testing strategies in schools: a multicountry modelling analysis.BMJ open · 2024Article
- Article
- Estimating the potential impact and diagnostic requirements for SARS-CoV-2 test-and-treat programs.Nature communications · 2023Article
- Surveillance for variants of SARS-CoV-2 to inform risk assessments.Bulletin of the World Health Organization · 2023Article
- Development of practical techniques for simultaneous detection and distinction of current and emerging SARS-CoV-2 variants.Analytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2023Review
- Genomic and Temporal Analysis of Deletions Correlated to qRT-PCR Dropout in N Gene in Alpha, Delta and Omicron Variants.Viruses · 2023Article
- Review
- When to update COVID-19 vaccine composition.Nature medicine · 2023Article
Corrections and comments
- Update of
Authors and funding
12 authors at 5 institutions in 3 countries.
Funding
Abstract
The first step in SARS-CoV-2 genomic surveillance is testing to identify people who are infected. However, global testing rates are falling as we emerge from the acute health emergency and remain low in many low- and middle-income countries (mean = 27 tests per 100,000 people per day). We simulated COVID-19 epidemics in a prototypical low- and middle-income country to investigate how testing rates, sampling strategies and sequencing proportions jointly impact surveillance outcomes, and showed that low testing rates and spatiotemporal biases delay time to detection of new variants by weeks to months and can lead to unreliable estimates of variant prevalence, even when the proportion of samples sequenced is increased. Accordingly, investments in wider access to diagnostics to support testing rates of approximately 100 tests per 100,000 people per day could enable more timely detection of new variants and reliable estimates of variant prevalence. The performance of global SARS-CoV-2 genomic surveillance programs is fundamentally limited by access to diagnostic testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.